Differentiated thyroid cancer: role of the lymph node dissection

Area of Science:

• Endocrinology
• Surgical Oncology
• Nuclear Medicine

Background:

• Differentiated thyroid cancer (DTC) is the most common endocrine malignancy.
• Total thyroidectomy is the standard treatment, but lymph node dissection extent is debated.
• Lack of prospective trials hinders definitive guidelines on central lymph node dissection (CLND).

Purpose of the Study:

• To evaluate the benefits and risks of central lymph node dissection (CLND) in differentiated thyroid cancer (DTC).
• To determine if CLND improves disease-specific survival and reduces recurrence compared to total thyroidectomy alone.
• To define criteria for selective CLND in papillary thyroid cancer (PTC).

Main Methods:

• Review of literature and consensus guidelines regarding thyroid cancer treatment.
• Analysis of risks (hypoparathyroidism, nerve injury) versus benefits (recurrence, survival) of CLND.
• Identification of high-risk patient criteria for selective CLND.

Main Results:

• CLND may decrease PTC recurrence and improve disease-specific survival.
• CLND increases the risk of permanent hypoparathyroidism and nerve injury.
• Therapeutic modified radical neck dissection (MRND) is reserved for extensive nodal involvement.

Conclusions:

• Selective CLND, performed by experienced surgeons, is recommended for high-risk PTC patients (age ≥50, large tumors, extrathyroid extension).
• CLND can be a viable alternative to routine prophylactic MRND.
• Careful patient selection is crucial to balance benefits against potential complications.